Market Closed -
Euronext Paris
16:35:26 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
2.95
EUR
|
0.00%
|
|
+1.03%
|
-35.87%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
120.2
|
139.1
|
65.75
|
11.38
|
27.94
|
17.92
|
-
|
Enterprise Value (EV)
1 |
61.09
|
122.1
|
57.43
|
-13.85
|
27.94
|
18.37
|
28.47
|
P/E ratio
|
-1.92
x
|
-1.78
x
|
-0.93
x
|
-36.7
x
|
-
|
-2.09
x
|
-3.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
22.7
x
|
37.4
x
|
15.7
x
|
0.37
x
|
-
|
17.1
x
|
11.2
x
|
EV / Revenue
|
11.6
x
|
32.8
x
|
13.7
x
|
-0.45
x
|
-
|
17.5
x
|
17.8
x
|
EV / EBITDA
|
-1.02
x
|
-1.91
x
|
-1.12
x
|
-7.59
x
|
-
|
-1.05
x
|
-1.58
x
|
EV / FCF
|
-0.96
x
|
-2.31
x
|
-1.01
x
|
0.43
x
|
-
|
91.9
x
|
24.8
x
|
FCF Yield
|
-104%
|
-43.3%
|
-99.4%
|
230%
|
-
|
1.09%
|
4.04%
|
Price to Book
|
1.4
x
|
4.93
x
|
2.2
x
|
0.48
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,794
|
1,956
|
3,102
|
3,102
|
6,075
|
6,075
|
-
|
Reference price
2 |
67.00
|
71.10
|
21.20
|
3.668
|
4.600
|
2.950
|
2.950
|
Announcement Date
|
16/03/20
|
08/03/21
|
27/04/22
|
22/03/23
|
20/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
5.283
|
3.718
|
4.18
|
31
|
-
|
1.05
|
1.6
|
EBITDA
1 |
-59.86
|
-63.84
|
-51.14
|
1.824
|
-
|
-17.5
|
-18
|
EBIT
1 |
-64.07
|
-68.83
|
-56.52
|
-2.796
|
-23.66
|
1
|
3.55
|
Operating Margin
|
-1,212.83%
|
-1,851.32%
|
-1,352.03%
|
-9.02%
|
-
|
95.24%
|
221.87%
|
Earnings before Tax (EBT)
|
-62.66
|
-73.3
|
-53.8
|
-
|
-
|
-
|
-
|
Net income
1 |
-62.66
|
-73.3
|
-53.8
|
-0.227
|
-23.49
|
-0.9
|
1.05
|
Net margin
|
-1,186.05%
|
-1,971.49%
|
-1,287.01%
|
-0.73%
|
-
|
-85.71%
|
65.62%
|
EPS
2 |
-34.90
|
-39.90
|
-22.70
|
-0.1000
|
-
|
-1.410
|
-0.9500
|
Free Cash Flow
1 |
-63.43
|
-52.86
|
-57.07
|
-31.85
|
-
|
0.2
|
1.15
|
FCF margin
|
-1,200.59%
|
-1,421.71%
|
-1,365.26%
|
-102.75%
|
-
|
19.05%
|
71.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
109.52%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
08/03/21
|
27/04/22
|
22/03/23
|
20/03/24
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 S1
|
2022 Q3
|
---|
Net sales
1 |
2.318
|
1.849
|
1.869
|
2.27
|
1.13
|
0.96
|
0.539
|
-
|
0.47
|
EBITDA
|
-30.71
|
-33.63
|
-30.98
|
-26.47
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-33.83
|
-35.37
|
-33.46
|
-28.97
|
-14.6
|
-13.77
|
-12.52
|
-
|
-
|
Operating Margin
|
-1,459.4%
|
-1,912.87%
|
-1,790.42%
|
-1,276.04%
|
-1,292.04%
|
-1,434.38%
|
-2,321.89%
|
-
|
-
|
Earnings before Tax (EBT)
|
-33.38
|
-34.96
|
-38.34
|
-27.95
|
-13.63
|
-
|
-11.91
|
-
|
-
|
Net income
1 |
-33.37
|
-34.96
|
-38.34
|
-27.95
|
-13.63
|
-
|
-11.91
|
-1.024
|
-5.139
|
Net margin
|
-1,439.73%
|
-1,890.86%
|
-2,051.26%
|
-1,231.37%
|
-1,206.19%
|
-
|
-2,209.83%
|
-
|
-1,093.4%
|
EPS
|
-18.60
|
-19.50
|
-20.40
|
-12.20
|
-
|
-
|
-
|
-0.3000
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
21/09/20
|
08/03/21
|
20/09/21
|
21/11/22
|
27/04/22
|
12/05/22
|
12/09/22
|
21/11/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
0.45
|
10.6
|
Net Cash position
1 |
59.1
|
17
|
8.32
|
25.2
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.0257
x
|
-0.5861
x
|
Free Cash Flow
1 |
-63.4
|
-52.9
|
-57.1
|
-31.8
|
-
|
0.2
|
1.15
|
ROE (net income / shareholders' equity)
|
-54.2%
|
-131%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
47.70
|
14.40
|
9.640
|
7.570
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-24.10
|
-
|
-
|
-
|
-
|
2.700
|
3.400
|
Capex
1 |
20.1
|
1.14
|
0.3
|
-
|
-
|
0.5
|
0.5
|
Capex / Sales
|
380.79%
|
30.63%
|
7.13%
|
-
|
-
|
47.62%
|
31.25%
|
Announcement Date
|
16/03/20
|
08/03/21
|
27/04/22
|
22/03/23
|
20/03/24
|
-
|
-
|
Last Close Price
2.95
EUR Average target price
6.85
EUR Spread / Average Target +132.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|